Literature DB >> 21767368

Opportunistic illnesses in Brazilian children with AIDS: results from two national cohort studies, 1983-2007.

Alberto N Ramos1, Luiza H Matida, Norman Hearst, Jorg Heukelbach.   

Abstract

BACKGROUND: HAART has significantly reduced AIDS-related morbidity in children. However, limited evidence is available from developing countries regarding patterns of opportunistic illnesses. We describe these events and their associated factors in children with AIDS in Brazil.
METHODS: This study is based on two representative retrospective multi-center cohorts including a total 1,859 children with AIDS, infected via mother-to-child transmission (MTCT), between 1983-2002. Opportunistic illnesses were described and analyzed over time. The association of demographic, clinical and operational data with the occurrence of opportunistic diseases was assessed.
RESULTS: In total, 1,218 (65.5%) had at least one event of an opportunistic disease. Variables significantly associated with occurrence of these events included: region of residence (OR 2.68-11.33, as compared to the Northern region), age < 1 year at diagnosis (OR 2.56, 95% CI 1.81-3.61, p < 0.001), and non-performance of MTCT prevention measures (OR 1.58, 95% CI 1.21-2.07, p < 0.001). Protective factors included year of HIV diagnosis in the HAART era (OR 0.34, 95% CI 0.15-0.76, p = 0.009) and ART use (OR 0.58, 95% CI 0.44-0.77, p < 0.001). In both periods bacterial infections represented the most common opportunistic events (58.6 vs. 34.7%; p < 0.001), followed by Pneumocystis jirovecii pneumonia (21.9 vs. 13.2%; p < 0.001), and bacterial meningitis/sepsis (16.8 vs. 7.4%; p < 0.001).
CONCLUSIONS: Despite the significant reduction in recent years, opportunistic illnesses are still common in Brazilian children with AIDS in the HAART era, especially bacterial diseases. The data reinforce the need for scaling up prevention of MTCT, early diagnosis of infection, and improvement of comprehensive pediatric care.

Entities:  

Year:  2011        PMID: 21767368      PMCID: PMC3150241          DOI: 10.1186/1742-6405-8-23

Source DB:  PubMed          Journal:  AIDS Res Ther        ISSN: 1742-6405            Impact factor:   2.250


  29 in total

1.  Fluctuations in symptoms in human immunodeficiency virus-infected children: the first 10 years of life.

Authors:  L Gray; M L Newell; C Thorne; C Peckham; J Levy
Journal:  Pediatrics       Date:  2001-07       Impact factor: 7.124

2.  AIDS by mother-to-child transmission: survival analysis of cases followed from 1983 to 2002 in different regions of Brazil.

Authors:  Luiza Harunari Matida; Alberto Novaes Ramos; José Eduardo Cajado Moncau; Luiz Francisco Marcopito; Heloisa Helena de Sousa Marques; Regina Célia Menezes Succi; Marinella Della Negra; Norman Hearst
Journal:  Cad Saude Publica       Date:  2007       Impact factor: 1.632

3.  Optimal management of HIV-infected women during pregnancy and delivery: an audit of compliance with recommendations.

Authors:  Aline Vandermaelen; Patricia Barlow; Yannick Manigart; Marc Hainaut; Tessa Goetghebuer; Jack Levy; Michèle Gerard; Serge Rozenberg
Journal:  J Womens Health (Larchmt)       Date:  2009-11       Impact factor: 2.681

4.  Effectiveness of highly active antiretroviral therapy in HIV-positive children: evaluation at 12 months in a routine program in Cambodia.

Authors:  Bart Janssens; Brian Raleigh; Seithaboth Soeung; Kazumi Akao; Vantha Te; Jitendra Gupta; Mean Chhy Vun; Nathan Ford; Janin Nouhin; Eric Nerrienet
Journal:  Pediatrics       Date:  2007-10-22       Impact factor: 7.124

5.  Impact of highly active antiretroviral therapy (HAART) on AIDS and death in a cohort of vertically HIV type 1-infected children: 1980-2006.

Authors:  Claudia Palladino; Jose M Bellón; Inmaculada Jarrín; Maria Dolores Gurbindo; M Isabel De José; José T Ramos; M Isabel González-Iome; Maria José Mellado; José Beceiro; Julia Del Amo; M Angeles Muñoz-Fernández
Journal:  AIDS Res Hum Retroviruses       Date:  2009-11       Impact factor: 2.205

6.  Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study.

Authors:  Kunjal Patel; Miguel A Hernán; Paige L Williams; John D Seeger; Kenneth McIntosh; Russell B Van Dyke; George R Seage
Journal:  Clin Infect Dis       Date:  2008-02-15       Impact factor: 9.079

Review 7.  Effectiveness of pediatric antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis.

Authors:  Andrea L Ciaranello; Yuchiao Chang; Andrea V Margulis; Adam Bernstein; Ingrid V Bassett; Elena Losina; Rochelle P Walensky
Journal:  Clin Infect Dis       Date:  2009-12-15       Impact factor: 9.079

8.  Changing patterns of clinical events in perinatally HIV-1-infected children during the era of HAART.

Authors:  Elena Chiappini; Luisa Galli; Pier-Angelo Tovo; Clara Gabiano; Catiuscia Lisi; Guido Castelli Gattinara; Susanna Esposito; Alessandra Viganò; Carlo Giaquinto; Raffaella Rosso; Alfredo Guarino; Maurizio de Martino
Journal:  AIDS       Date:  2007-07-31       Impact factor: 4.177

9.  Early antiretroviral therapy and mortality among HIV-infected infants.

Authors:  Avy Violari; Mark F Cotton; Diana M Gibb; Abdel G Babiker; Jan Steyn; Shabir A Madhi; Patrick Jean-Philippe; James A McIntyre
Journal:  N Engl J Med       Date:  2008-11-20       Impact factor: 91.245

10.  Morbidity, mortality, and response to treatment by children in the United Kingdom and Ireland with perinatally acquired HIV infection during 1996-2006: planning for teenage and adult care.

Authors:  Ali Judd; Katja Doerholt; Pat A Tookey; Mike Sharland; Andrew Riordan; Esse Menson; Vas Novelli; E G Hermione Lyall; Janet Masters; Gareth Tudor-Williams; Trinh Duong; Di M Gibb
Journal:  Clin Infect Dis       Date:  2007-08-27       Impact factor: 9.079

View more
  1 in total

1.  Incidence of Pneumocystis jirovecii and Adverse Events Associated With Pneumocystis Prophylaxis in Children Receiving Glucocorticoids.

Authors:  Matthew L Basiaga; Michelle E Ross; Jeffrey S Gerber; Alexis Ogdie
Journal:  J Pediatric Infect Dis Soc       Date:  2018-12-03       Impact factor: 3.164

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.